# To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

> **NCT00910871** · PHASE2 · COMPLETED · sponsor: **Janssen Infectious Diseases BVBA** · enrollment: 241 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** TMC207
- **DRUG:** Background Regimen (BR) for MDR-TB

## Key facts

- **NCT ID:** NCT00910871
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-03
- **Final completion:** 2013-01
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2015-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910871, "To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00910871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*